N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid-2-ylsulfonamide | 358972-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid-2-ylsulfonamide
• 英文别名: N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]pyridine-2-sulfonamide
• CAS: 358972-06-2
• 化学式: C₂₁H₁₉Cl₂N₃O₂S
• 分子量: 448.373
• InChiKey: DVQHGCWTAZWUAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
  申请人：——

  公开号：US20020019383A1

  公开（公告）日：2002-02-14

  The present invention relates to pharmaceutical compositions containing, as active ingredient, a compound of formula: 1 in which R 1 represents a radical —NHCOR 4 or —N(R 5 )—Y—R 6 , Y is CO or SO 2 , R 4 represents a radical -alk-SO 2 —R 11 , -alk-SO 2 —CH═CH—R 11 or Het substituted with —SO 2 —R 11 or a phenyl radical substituted with —SO 2 —R 11 or -alk-SO 2 —R 11 , R 5 represents a hydrogen atom or an alkyl radical, R6 represents a phenylalkyl, Het or Ar radical, to the novel derivatives of formula (I) and to their preparation.

  本发明涉及包含作为活性成分的公式1化合物的药物组合物：其中R1代表—NHCOR4或—N(R5)—Y—R6，Y是CO或SO2，R4代表—alk-SO2—R11，-alk-SO2—CH═CH—R11或Het，或用—SO2—R11或—SO2—R11或-alk-SO2—R11取代的苯基自由基，R5代表氢原子或烷基自由基，R6代表苯基烷基，Het或Ar自由基，以及新颖的公式(I)衍生物及其制备方法。
• Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
  申请人：——

  公开号：US20020091114A1

  公开（公告）日：2002-07-11

  The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.

  本发明涉及CB1受体拮抗剂与西布曲明的组合，涉及包含它们的药物组合物以及它们在治疗肥胖症中的应用。
• Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia
  申请人：BLACK Mark

  公开号：US20080221078A1

  公开（公告）日：2008-09-11

  The present invention discloses and claims a method of treating cognition deficits in a patient suffering from schizophrenia by administering to said patient a therapeutically effective amount of a CB1 receptor antagonist as described herein. In another aspect, this invention also discloses and claims a combination of one or more CB1 receptor antagonists and of one or more antipsychotic agents useful in the treatment of psychiatric disorders. The combination of this invention provides synergistic results in that the combination improves positive and negative symptoms of schizophrenia, weight gain and catalepsy.

  本发明揭示并声明了一种治疗患有精神分裂症的患者认知缺陷的方法，通过向该患者施用本文所述的CB1受体拮抗剂的治疗有效剂量。在另一个方面，本发明还揭示并声明了一种CB1受体拮抗剂和一种或多种抗精神病药物的组合，用于治疗精神障碍。本发明的这种组合提供了协同效果，改善了精神分裂症的阳性和阴性症状、体重增加和猫病。
• Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
  申请人：Aventis Pharma S.A.

  公开号：US20040209861A1

  公开（公告）日：2004-10-21

  The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their use in the treatment of Parkinson's disease.

  本发明涉及一种或多种CB1拮抗剂氮杂环衍生物和一种或多种促进脑内多巴胺能神经传递的产物的组合，以及包含它们的制药组合物，用于治疗帕金森病。
• Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositons comprising them and their use in the treatment of obesity
  申请人：Piot-Grosjean Odile

  公开号：US20050032773A1

  公开（公告）日：2005-02-10

  The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.

  本发明涉及一种 CB1 受体拮抗剂和西布曲明的组合、包含它们的药物组合物以及它们在治疗肥胖症中的用途。